XML 98 R87.htm IDEA: XBRL DOCUMENT v3.25.3
Earnings Per Common Share - EPS Under Basic and Diluted Computations (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Net income $ 2,358 $ 1,408 $ 6,393 [1] $ 4,102 [1]
Preferred stock dividends and other (81) (109) (343) (341)
Net Income Available to Common Stockholders $ 2,277 $ 1,299 $ 6,050 $ 3,761
Weighted-average common shares outstanding - basic (in shares) 1,806 1,829 1,815 1,827
Basic earnings per share (in USD per share) [2] $ 1.26 $ 0.71 $ 3.33 $ 2.06
Weighted-average common shares outstanding - diluted (in shares) 1,811 1,834 1,820 1,833
Diluted earnings per share (in USD per share) [2] $ 1.26 $ 0.71 $ 3.33 $ 2.05
Antidilutive stock options and restricted stock awards excluded from the calculation of diluted EPS (in shares) 9 14 13 18
Common Stock        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Net income $ 2,358 $ 1,369 $ 6,373 $ 3,988
Preferred stock dividends and other (81) (106) (342) (332)
Net Income Available to Common Stockholders $ 2,277 $ 1,263 $ 6,031 $ 3,656
Weighted-average common shares outstanding - basic (in shares) 1,806 1,778 1,807 1,776
Basic earnings per share (in USD per share) $ 1.26 $ 0.71 $ 3.33 $ 2.06
Reallocation of net income available to common stockholders as a result of conversion of nonvoting to voting shares $ 0 $ 36 $ 19 $ 105
Allocation of net income available to common stockholders: $ 2,277 $ 1,299 $ 6,050 $ 3,761
Conversion of nonvoting shares to voting shares (in shares) 0 51 8 51
Common stock equivalent shares related to stock incentive plans (in shares) 5 5 5 6
Weighted-average common shares outstanding - diluted (in shares) 1,811 1,834 1,820 1,833
Diluted earnings per share (in USD per share) $ 1.26 $ 0.71 $ 3.33 $ 2.05
Nonvoting Common Stock        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Net income $ 0 $ 39 $ 20 $ 114
Preferred stock dividends and other 0 (3) (1) (9)
Net Income Available to Common Stockholders $ 0 $ 36 $ 19 $ 105
Weighted-average common shares outstanding - basic (in shares) 0 51 51 51
Basic earnings per share (in USD per share) $ 0 $ 0.71 $ 0.37 $ 2.06
Reallocation of net income available to common stockholders as a result of conversion of nonvoting to voting shares $ 0 $ 0 $ 0 $ 0
Allocation of net income available to common stockholders: $ 0 $ 36 $ 19 $ 105
Conversion of nonvoting shares to voting shares (in shares) 0 0 0 0
Common stock equivalent shares related to stock incentive plans (in shares) 0 0 0 0
Weighted-average common shares outstanding - diluted (in shares) 0 51 51 51
Diluted earnings per share (in USD per share) $ 0 $ 0.71 $ 0.37 $ 2.05
Consolidated Common Stock        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Net income $ 2,358   $ 6,393  
Preferred stock dividends and other (81)   (343)  
Net Income Available to Common Stockholders $ 2,277   $ 6,050  
Weighted-average common shares outstanding - basic (in shares) 1,806   1,815  
Basic earnings per share (in USD per share) $ 1.26   $ 3.33  
Reallocation of net income available to common stockholders as a result of conversion of nonvoting to voting shares $ 0   $ 0  
Allocation of net income available to common stockholders: $ 2,277   $ 6,050  
Conversion of nonvoting shares to voting shares (in shares) 0   0  
Common stock equivalent shares related to stock incentive plans (in shares) 5   5  
Weighted-average common shares outstanding - diluted (in shares) 1,811   1,820  
Diluted earnings per share (in USD per share) $ 1.26   $ 3.33  
[1] Certain prior year amounts have been reclassified to conform to the current year presentation. See Note 1 for additional information.
[2] For additional information on earnings per common shares outstanding for both voting and nonvoting common stock, see Note 16.